BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, January 22, 2026
Home » Authors » Kim Coghill

Kim Coghill

Articles

ARTICLES

Roche Paying Isotechnika Up To $215M For Transplantation Drug

April 10, 2002
By Kim Coghill
Hoffmann-La Roche Inc. agreed to spend upward of $215 million in a global partnership with Isotechnika Inc. to develop a transplantation drug with blockbuster potential. (BioWorld Today)
Read More

XOMA, Genentech Set Back On Development Of Xanelim

April 8, 2002
By Kim Coghill
XOMA Ltd.’s stock took a painful hit Friday when the company and its partner, Genentech Inc., released poor preliminary data from a pharmacokinetic study of Xanelim, a psoriasis drug. (BioWorld Today)
Read More

XOMA, Genentech Set Back On Development Of Xanelim

April 8, 2002
By Kim Coghill
XOMA Ltd.’s stock took a painful hit Friday when the company and its partner, Genentech Inc., released poor preliminary data from a pharmacokinetic study of Xanelim, a psoriasis drug. (BioWorld Today)
Read More

CancerVax’s Second Round Raises $55M For Canvaxin

April 5, 2002
By Kim Coghill
CancerVax Corp., a young company studying a vaccine for melanoma and colon cancer, on Monday said it raised $55 million in its second round of financing through the private placement of preferred stock. (BioWorld Today)
Read More

CancerVax’s Second Round Raises $55M For Canvaxin

April 5, 2002
By Kim Coghill
CancerVax Corp., a young company studying a vaccine for melanoma and colon cancer, on Monday said it raised $55 million in its second round of financing through the private placement of preferred stock. (BioWorld Today)
Read More

Inspire Expects Better Results As It Starts Phase III Of INS365

April 4, 2002
By Kim Coghill

Inspire Expects Better Results As It Starts Phase III Of INS365

April 4, 2002
By Kim Coghill

Ambit Enters Collaboration With AstraZeneca On Protein Targets

April 3, 2002
By Kim Coghill

Ambit Enters Collaboration With AstraZeneca On Protein Targets

April 3, 2002
By Kim Coghill

Adolor Moving Analgesic Back To Phase I To Work On Dosing

April 2, 2002
By Kim Coghill
View All Articles by Kim Coghill

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Jan 22, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Jan. 22, 2026.
  • Illustration of human body surrounded by DNA, cell and drug icons

    Cell/gene therapy sector now sustainable; China competition mounting

    BioWorld
    There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
  • Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal

    BioWorld
    With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
  • Illustration of magnifying glass inspecting brain

    Neurotrimin unveiled as marker in intellectual disability

    BioWorld Science
    Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing